- Home
- OPRT vs NMRA Comparison
OPRT vs NMRA Comparison
Compare OPRT & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | OPRT | NMRA |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | United States | United States |
| Employees | 1578 | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.5M | 311.3M |
| IPO Year | 2019 | 2023 |
Fundamental Metrics
Financial Performance| Metric | OPRT | NMRA |
|---|---|---|
| Price | $6.19 | $1.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $7.00 | ★ $7.50 |
| AVG Volume (30 Days) | 553.1K | ★ 3.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 127.18 | 5.23 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $956,685,000.00 | N/A |
| Revenue This Year | $32.79 | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $113.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.03 | $0.83 |
| 52 Week High | $7.33 | $3.65 |
Technical Indicators
Market Signals| Indicator | OPRT | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 62.80 | 47.42 |
| Support Level | $4.95 | $1.50 |
| Resistance Level | $6.19 | $2.00 |
| Average True Range (ATR) | 0.31 | 0.13 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 75.49 | 32.88 |
Price Performance
Historical ComparisonAbout OPRT Oportun Financial Corporation
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.